| Schedule of account payable and accrued expenses |
|
|
|
|
|
|
|
|
| |
|
June 30,
2026 |
|
|
October 31,
2025 |
|
| Accrued payroll related liabilities |
|
$ |
667,000 |
|
|
$ |
667,000 |
|
| Lab equipment and supplies payables |
|
|
41,000 |
|
|
|
120,000 |
|
| Clinical trial and research payables |
|
|
638,000 |
|
|
|
634,000 |
|
| Legal fees payable |
|
|
282,000 |
|
|
|
244,000 |
|
| Other professional fees payable |
|
|
95,000 |
|
|
|
121,000 |
|
| Interest payable |
|
|
15,000 |
|
|
|
1,000 |
|
| Royalty payable |
|
|
50,000 |
|
|
|
100,000 |
|
| Accrued commissions payable |
|
|
117,000 |
|
|
|
37,000 |
|
| Construction payables |
|
|
9,000 |
|
|
|
9,000 |
|
| Accrued Serephon compensation |
|
|
53,000 |
|
|
|
- |
|
| Other payables and accrued expenses |
|
|
108,000 |
|
|
|
47,000 |
|
| Total Accounts Payable and Accrued Expenses |
|
$ |
2,075,000 |
|
|
$ |
1,980,000 |
|